Concepedia

Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Tim G. Call, Clive S. Zent, Betsy LaPlant, Deborah A. Bowen, Michelle Roos, Charla Secreto, Asish K. Ghosh, Brian Kabat, Mao-Jung Lee,

Journal of Clinical Oncology · 2009 · 182 citations · 62 references

DOIFull text

Open access

Abstract

Daily oral EGCG in the Polyphenon E preparation was well tolerated by CLL patients in this phase I trial. Declines in ALC and/or lymphadenopathy were observed in the majority of patients. A phase II trial to evaluate efficacy using 2,000 mg twice a day began in November 2007.

References

62

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text

Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia

Terry J. Hamblin, Zadie Davis, Anne Gardiner et al. · Blood · 1999 · 2.7K citations

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

Cheson Bd, J M Bennett, Michael R. Grever et al. · Blood · 1996 · 1.8K citations

Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.

Ming Zhu Fang, Yimin Wang, Ni Ai et al. · PubMed · 2003 · 1.1K citations

, , +19

Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study

Saverio Bettuzzi, Maurizio Brausi, Federica Rizzi et al. · Cancer Research · 2006 · 811 citations · Full text